Ro 25-6981NMDA receptors blocker CAS# 169274-78-6 |
- AVL-292
Catalog No.:BCC1385
CAS No.:1202757-89-8
- QL47
Catalog No.:BCC3920
CAS No.:1469988-75-7
- PCI 29732
Catalog No.:BCC4100
CAS No.:330786-25-9
- CGI-1746
Catalog No.:BCC1473
CAS No.:910232-84-7
- PCI-32765 (Ibrutinib)
Catalog No.:BCC1266
CAS No.:936563-96-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 169274-78-6 | SDF | Download SDF |
| PubChem ID | 6604887 | Appearance | Powder |
| Formula | C22H29NO2 | M.Wt | 339.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 100 mg/mL (294.58 mM; Need ultrasonic) | ||
| Chemical Name | 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol | ||
| SMILES | CC(CN1CCC(CC1)CC2=CC=CC=C2)C(C3=CC=C(C=C3)O)O | ||
| Standard InChIKey | WVZSEUPGUDIELE-HTAPYJJXSA-N | ||
| Standard InChI | InChI=1S/C22H29NO2/c1-17(22(25)20-7-9-21(24)10-8-20)16-23-13-11-19(12-14-23)15-18-5-3-2-4-6-18/h2-10,17,19,22,24-25H,11-16H2,1H3/t17-,22+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ro 25-6981 is a potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit. IC50 values are 0.009 and 52 μM for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respectively.
IC50 value: 9 nM [1]
Target: NMDA receptor subtype of NR1C & NR2B
in vitro: Ro 25-6981 inhibited 3H-MK-801 binding to rat forebrain membranes in a biphasic manner with IC50 values of 0.003 microM and 149 microM for high- (about 60%) and low-affinity sites, respectively. NMDA receptor subtypes expressed in Xenopus oocytes were blocked with IC50 values of 0.009 microM and 52 microM for the subunit combinations NR1C & NR2B and NR1C & NR2A, respectively, which indicated a >5000-fold selectivity [1]. Increasing the concentration of spermidine did not change the efficacy of RO 25-6981 and minimally changed the IC(50) value. Epsilon1Q336R receptors were more inhibited by ifenprodil and RO 25-9681 than wildtype epsilon1 receptors in ligand binding assays but not in functional assays [2].
in vivo: Intrathecal injection of Ro 25-6981 significantly enhanced the paw withdrawal mechanical threshold and paw withdrawal thermal latency after the operation. Significant change has been observed after intrathecal injection of 800.0 μg of Ro 25-6981 and at 2h after operation in the oblique pull test degree and BBB rating score. Pretreatment of Ro 25-6981 decreased the high level expression of NR2B with tyrosine phosphorylation in spinal dorsal horn of the rat model after the operation [3]. References: | |||||
Ro 25-6981 Dilution Calculator
Ro 25-6981 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9458 mL | 14.7288 mL | 29.4577 mL | 58.9154 mL | 73.6442 mL |
| 5 mM | 0.5892 mL | 2.9458 mL | 5.8915 mL | 11.7831 mL | 14.7288 mL |
| 10 mM | 0.2946 mL | 1.4729 mL | 2.9458 mL | 5.8915 mL | 7.3644 mL |
| 50 mM | 0.0589 mL | 0.2946 mL | 0.5892 mL | 1.1783 mL | 1.4729 mL |
| 100 mM | 0.0295 mL | 0.1473 mL | 0.2946 mL | 0.5892 mL | 0.7364 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ro 25-6981 is a high-affinity, potent and selective blocker of N-methyl- D-aspartate (NMDA) receptors[1].
Ro 25-6981 has shown a biphasic concentration-effect relationship in inhibiting 3H-MK-801 binding to rat forebrain membranes with the mean Kd values of 0.003μM and 149μM for the high-affinity binding and the low-affinity binding, respectively. In addition, the IC50 values of Ro 25-6981 for antagonism of the NR1C & NR2B, NR1F &NR2B and NR1C & NR2A receptors are 0.009μM, 0.017μM and 52μM, respectively. Moreover, Ro 25-6981 has been revealed to protect the neurons in concentration-dependent fashion in both two toxicity tests with the IC50 values of 0.4μM in the glutamate toxicity test and 0.04μMin the OGD test[1].
References:
[1] Fischer G1, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, Kemp JA. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther. 1997 Dec;283(3):1285-92.
- Fmoc-Phe(4-F)-OH
Catalog No.:BCC3220
CAS No.:169243-86-1
- Dihydropedicin
Catalog No.:BCN4692
CAS No.:169234-89-3
- Trametol
Catalog No.:BCN6924
CAS No.:169217-47-4
- MTPG
Catalog No.:BCC6820
CAS No.:169209-66-9
- MPPG
Catalog No.:BCC6818
CAS No.:169209-65-8
- MSPG
Catalog No.:BCC6819
CAS No.:169209-64-7
- (2R,4R)-APDC
Catalog No.:BCC6969
CAS No.:169209-63-6
- 4'-O-Methylcoumestrol
Catalog No.:BCN7226
CAS No.:1690-62-6
- Tropanyl phenylacetate
Catalog No.:BCN1927
CAS No.:1690-22-8
- RS 67506 hydrochloride
Catalog No.:BCC6878
CAS No.:168986-61-6
- RS 67333 hydrochloride
Catalog No.:BCC5693
CAS No.:168986-60-5
- Z-Tyr(tBu)-OH.DCHA
Catalog No.:BCC2745
CAS No.:16879-90-6
- Nebivolol hydrochloride
Catalog No.:BCC9099
CAS No.:169293-50-9
- Boc-D-Orn(Z)-OH
Catalog No.:BCC3431
CAS No.:16937-92-1
- Boc-D-Leu-OH.H2O
Catalog No.:BCC3409
CAS No.:16937-99-8
- 3β,7β,15β-trihydroxy-11-oxo-lanosta-8-en-24->20 lactone
Catalog No.:BCC8643
CAS No.:1694587-15-9
- Boc-N-Me-Ala-OH
Catalog No.:BCC3209
CAS No.:16948-16-6
- RS 17053 hydrochloride
Catalog No.:BCC6874
CAS No.:169505-93-5
- Protostemotinine
Catalog No.:BCN8314
CAS No.:169534-85-4
- IRL-2500
Catalog No.:BCC7192
CAS No.:169545-27-1
- Fmoc-Ala(4-pyridyl)-OH
Catalog No.:BCC3327
CAS No.:169555-95-7
- Otosenine
Catalog No.:BCN2107
CAS No.:16958-29-5
- Florosenine
Catalog No.:BCN2108
CAS No.:16958-30-8
- Floridanine
Catalog No.:BCN2103
CAS No.:16958-31-9
Neurogenesis enhancer RO 25-6981 facilitates repeated spatial learning in adult rats.[Pubmed:23113280]
Bull Exp Biol Med. 2012 Sep;153(5):764-6.
The effects of Ro 25-6981 (selective NMDA receptor blocker) in a dose stimulating neurogenesis on repeated learning, reversal learning, and memory reconsolidation were studied in adult rats in Morris water maze. Ro 25-6981 facilitated repeated learning 13 days after injection, but did not influence reversal learning. The blocker injected directly before reminder did not disturb repeated learning and reversal learning in Morris water maze. These effects of Ro 25-6981 on the dynamics of repeated learning seemed to be due to its effects on neurogenesis processes in adult brain.
Different action of a specific NR2B/NMDA antagonist Ro 25-6981 on cortical evoked potentials and epileptic afterdischarges in immature rats.[Pubmed:25446739]
Brain Res Bull. 2015 Feb;111:1-8.
Ro 25-6981 maleate is a highly selective and activity-dependent antagonist of NMDA ionotropic glutamate receptors containing NR2B subunit (NR2B/NMDARs). The aim of our study was to investigate the influence of Ro 25-6981 administration in developing rats on physiological (single and paired pulse cortical interhemispheric evoked potentials) and epileptic brain activity (cortical afterdischarges (ADs)). Electrophysiological experiments were performed in animals with epidurally implanted electrodes at postnatal days (P) P12, P18, and P25. The drug was injected intraperitoneally at a dose of 1 or 3mg/kg. Control animals were injected with saline (1ml/kg). Single interhemispheric responses were evoked with 0.5-ms biphasic pulses with intensities increasing from 0.4 to 5mA, paired-pulse responses were elicited by twofold threshold intensity. The ADs were elicited by series of 15-s of 1-ms pulses at 8-Hz frequency. Firstly, six stimulations with stable suprathreshold intensity repeated at 30-min intervals were used to determine the time course of Ro 25-6981 effects against ADs in P12 animals. Secondly, similar experiment was performed in all age groups of animals but with 20-min intervals as well as a further experiment using stimulations with stepwise intensities increasing at 10-min intervals from 0.2 to 15 mA. Pretreatment with the 3-mg/kg (but not the lower) dose of Ro 25-9681 decreased significantly the amplitude of single responses evoked with higher stimulation intensities in P12 and P18 animals. Both doses affected responses in P25 animals, only the 1-mg/kg dose was more efficacious than the 3-mg/kg one. Paired pulse responses were not affected by either dose of Ro 25-6981 in any age group. Ro 25-9681 clearly influenced the duration of ADs only in P12 animals. The 1-mg/kg dose did not change the duration of ADs whereas the 3-mg/kg dose suppressed progressive prolongation of ADs with repeated stimulations. This effect was seen even 110-min after the drug injection. The modification of ADs, i.e. stimulations with stepwise increasing intensities (10 min intervals) was used to demonstrate possible dependence on activity. The Ro 25-6981 was administered immediately after the 4-mA stimulation (i.e. when rats experienced six ADs on the average). The 3-mg/kg dose resulted in shorter ADs after high stimulation intensities in P12. There were no significant effects in older animals, only a tendency to ADs shortening was observed in P25 rats. In conclusion, our results indicate that Ro 25-6981 as a selective antagonist of NR2B/NMDARs exhibit age- and activation-dependent anticonvulsant action at early postnatal development. In contrast, the influence of Ro 25-6981 on physiological excitability induced by single pulse stimulation of sensorimotor cortex does not depend on age. This compound may thus represent a useful antiepileptic agent in immature brain since its action against ADs prolongation can be observed even 110 min after the single administration of the drug.
Effects of the GluN2B-NMDA receptor antagonist Ro 25-6981 on two types of behavioral flexibility in rats.[Pubmed:27871866]
Behav Brain Res. 2017 Feb 15;319:225-233.
Recent evidence has implicated N-methyl-d-aspartate receptors (NMDARs) in several aspects of learning and behavioral flexibility in rodents. Here, we examined the effects of treatment with Ro 25-6981, a selective antagonist of NMDARs containing GluN2B subunits, on two types of behavioral flexibility in rats, spatial reversal learning and set-shifting (spatial vs. motor strategy). To examine spatial reversal learning, rats were trained to swim to a hidden platform in a water maze over four days. On the following day, the platform was moved to a new location in the maze. Administration of Ro 25-6981 (10mg/kg) selectively impaired the early phase of reversal learning, but all rats learned to navigate to the new platform location over 12 trials. To examine set-shifting, independent groups of rats were trained to either swim to a fixed location (spatial strategy) or use a motor response (e.g., "turn left"; motor strategy) to find a hidden escape platform in a cross-shaped water maze apparatus; after task acquisition, rats were trained on the second, novel strategy (set-shift) following treatment with either Ro 25-6981 (10mg/kg) or saline. Administration of Ro 25-6981 had no effect on the ability of rats to perform the set-shift and use the new strategy to locate the escape platform. These results suggest that, in rats, spatial reversal learning, but not set-shifting, is sensitive to Ro-25-6981 treatment. Thus, NMDARs-GluN2B signaling may play a selective role in some forms of behavioral plasticity, particularly for situations involving the updating of information in the spatial domain.
Antinociception and prevention of hyperalgesia by intrathecal administration of Ro 25-6981, a highly selective antagonist of the 2B subunit of N-methyl-D-aspartate receptor.[Pubmed:24076088]
Pharmacol Biochem Behav. 2013 Nov;112:56-63.
BACKGROUND: NR2B subunits (NMDA receptor 2B subunit) play an important role in generation of pain and forming central sensitization of pain. Ro 25-6981, a highly selective NR2B antagonist, gained much attention in recent years. In this study, we used a rat model of incisional pain to investigate effects of postoperative analgesia and changes of postoperative hyperalgesia induced by remifentanil through the pretreatment of intrathecal administration with Ro 25-6981. METHODS: The behavioral changes of rats have been evaluated by the paw withdrawal mechanical threshold and paw withdrawal thermal latency after intrathecal injection of Ro 25-6981. The expression of NR2B with tyrosine phosphorylation in the spinal dorsal horn was analyzed by Western blotting. RESULTS: Intrathecal injection of Ro 25-6981 significantly enhanced the paw withdrawal mechanical threshold and paw withdrawal thermal latency after the operation. Significant change has been observed after intrathecal injection of 800.0 mug of Ro 25-6981 and at 2h after operation in the oblique pull test degree and BBB rating score. Pretreatment of Ro 25-6981 decreased the high level expression of NR2B with tyrosine phosphorylation in spinal dorsal horn of the rat model after the operation. CONCLUSIONS: Intrathecal injection of Ro 25-6981 had significant analgesic effects on incision pain in rats and effectively attenuated postoperative hyperalgesia induced by remifentanil.
